Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

Advances in Transdermal Drug Delivery: The Development of Microneedle Technology for Improved Therapeutic Outcomes

Shivshankar M. Nagrik[1], Vaishnavi S. Akhare[2], Manisha W. Bhade[3], Mohini R. Nayse[4], Ankita G. Gulhane[5], Shreya P. Bhorkhade[6], Shatrughna U. Nagrik[7] and Ashwini G. Verulkar[8]

[1]Master's Student, Department of Pharmaceutics, Amravati University, Buldhana, Maharashtra, INDIA.

[2,3,4,5,6]Student, Bachelor of Pharmacy, Amravati University, Buldhana, Maharashtra, INDIA.

[7]Assistant Professor, Bachelor of Pharmacy, Satyajeet College of Pharmacy, Mehkar, Maharashtra, INDIA.

[8]Student, Bachelor of Pharmacy Second Year, Amravati University, Buldhana, Maharashtra, INDIA.

[1]Corresponding Author: shivshankarnagrik11@gmail.com

ORCiD

https://orcid.org/0009-0009-2109-1865

www.jrasb.com || Vol. 3 No. 5 (2024): October Issue

Received: 16-10-2024	**Revised:** 24-10-2024	**Accepted:** 07-11-2024

ABSTRACT

Transdermal Drug Delivery Systems (TDDS) represent a significant advancement in therapeutic administration by allowing drugs to bypass the gastrointestinal system and first-pass hepatic metabolism, enhancing patient compliance, and enabling sustained drug release. However, traditional TDDS face limitations, including resistance from the skin's natural barrier and limited efficacy in delivering large or hydrophilic molecules. Microneedle (MN) technology offers a breakthrough solution, using minimally invasive micron-sized needles to bypass the stratum corneum, facilitating efficient drug delivery without significant pain or discomfort. This review explores the evolution and recent advancements in microneedle technology, highlighting its role in overcoming the limitations of conventional TDDS. Microneedles have been shown to enhance drug bioavailability, reduce side effects, and expand the range of deliverable therapeutics, including vaccines, insulin, and genetic materials. The development of bioinspired 4D microneedles further extends their application to diagnostics and cosmetic treatments, positioning MNs as a versatile tool in modern medicine. Key sections of the review focus on the types of microneedles—solid, coated, dissolving, hollow, and hydrogel-forming—and their respective fabrication methods, materials, and drug delivery mechanisms. The review also discusses the challenges related to scaling up production, ensuring consistent quality, and regulatory hurdles in achieving clinical approval. Future directions include the integration of microneedles with nanotechnology, combination therapies, and sustainable design, particularly in developing regions where biodegradable materials may address environmental and disposal concerns. The potential for microneedle technology to revolutionize transdermal drug delivery, diagnostics, and therapeutic monitoring is significant, with ongoing research paving the way for multifunctional applications that can reshape patient care and treatment modalities.

Keywords- Transdermal Drug Delivery Systems, Microneedle Technology, 4D microneedles, Laser cutting, FDA and EMA regulatory challenges.

I. INTRODUCTION

Transdermal Drug Delivery Systems (TDDS) are medical technologies designed to deliver therapeutic agents through the skin into the systemic circulation. This approach eliminates the gastrointestinal tract and first-pass hepatic metabolism, providing an alternative route for drugs often taken orally or intravenously. The objective of TDDS is to achieve regulated and prolonged

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

drug administration, hence enhancing treatment efficacy, compliance, and minimizing adverse effects.

Definition And General Benefits of TDDS: Described as Transdermal drug delivery systems (TDDS), is the method that involves transporting of drugs through the skin barrier lamella to the bloodstream without passing through the gastrointestinal tract; and which holds numerous benefits over the traditional method of drug delivery. The primary advantages include:

Avoidance of First-Pass Metabolism: Unlike the oral route of administration, where the drug is subjected to hepatic metabolism prior to entering systemic circulation, transdermal drug delivery systems (TDDS) directly administer the medication into the bloodstream [1].

Improved Patient Compliance: Transdermal Drug Delivery Systems (TDDS) are generally less irritating than injections, hence increasing adherence to prescribed medicines, particularly for chronic conditions necessitating prolonged treatment [2].

Sustained Drug Release: Transdermal Drug Delivery Systems (TDDS) administer medications in a controlled manner over a longer duration, resulting in homogenous plasma drug concentrations; thus, this improves drug delivery therapy and diminishes the frequency of dosage necessary.

Reduced Side Effects: The ability to directly deliver the medicine into the systemic blood stream in small controlled doses often makes the drug free of GI and system side effects [4].

Easy Termination of Drug Therapy: In instances of adverse responses, the prompt removal of the transdermal patch effectively ceases additional drug absorption, in contrast to oral or injectable drugs, which persist in the system for an extended duration [5].

1.1 Limitations of Traditional TDDS:

Although the numerous benefits of TDDS, conventional transdermal systems encounter significant barriers that restrict their extensive utilization:

Skin Barrier Resistance: The principal constraint of TDDS is the stratum corneum, the skin's outermost layer, which serves as a significant barrier to the absorption of most pharmaceuticals. Only lipophilic, low molecular weight medicines (typically <500 Da) can effectively permeate this barrier, thereby constraining the spectrum of therapeutic agents suitable for transdermal delivery [6]. This complicates the attainment of therapeutic levels for hydrophilic medicines and macromolecules such as peptides and proteins by transdermal drug delivery systems (TDDS).

Limited Drug Types: Due to the skin's barrier function, TDDS is unsuitable for delivering drugs with high molecular weights or those that require high systemic concentrations for efficacy. Molecules of such a size that they cannot be absorbed through skin in their pure form include insulin, vaccines, and other biologics [7].

Variable Absorption: The study is meant to clarify how the rate of drug absorption is influenced by skin condition, age, moisture levels, and the application site. Regional disparities in drug delivery rates may result in an uneven efficacy of therapies [8].

Skin Irritation: The prolonged use of TDDS may induce skin reactions, sensitization, or allergic responses in certain individuals, hence restricting the recommended duration of this system[9].

Inability to Deliver Bolus Doses: TDDS is intended for the continuous but controlled delivery of the drug and as such, it is unsuitable for the delivery of drugs that require an immediate onset of action or high initial doses (burst release) [10]. The mentioned above limitations explain the need for developing advanced transdermal delivery systems, for example, microneedle technology which is able to deliver even larger and more diverse molecule while passing through the skin barrier is the significant improvement in delivering drugs.

1.2. Microneedle Technology:

Microneedle technology is a sophisticated advancement in transdermal drug delivery systems (TDDS), addressing numerous constraints associated with conventional techniques like skin patches and injections. Microneedles (MNs) are minimally invasive devices that traverse the skin's stratum corneum, facilitating the direct administration of pharmaceuticals into deeper layers while minimizing pain and tissue damage. The principal mechanism comprises arrays of micron-scale needles constructed from materials such as silicon, metals, and biodegradable polymers. This facilitates the efficient administration of pharmaceuticals, vaccinations, and other therapeutic agents, while improving patient adherence and minimizing discomfort.

1.2.1. Evolution and Significance in Overcoming Traditional TDDS Barriers: Conventional transdermal medication administration is limited by the skin's inherent barrier, which blocks the passage of substantial or hydrophilic drug molecules. Microneedle technology overcomes this issue by forming microchannels in the skin, circumventing the barrier while minimizing the discomfort of hypodermic needles. The transition from solid to dissolvable microneedles has improved their therapeutic applications by providing customized release profiles and limiting the risks of infection or residue post-application [11].

Current research have created silicon-based microneedles for drug delivery[12] and dissolvable microneedles for vaccines and long-acting depot systems[13]. These improvements facilitate prolonged drug release and permit the transdermal administration of previously challenging medications. Current advancements encompass the utilization of 3D-printed microneedles, facilitating the customization of medication compositions and delivery rates [14].

1.3. Purpose of the Review:

Microneedle technology represents a groundbreaking approach for administering medication directly to the skin. Existing transdermal medication administration systems, such as patches, sometimes encounter difficulties in administering medicines with

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

high molecular weights or low skin solubility. Microneedles (MNs) are diminutive needles of micron scale that administer medication through the stratum corneum into the epidermis or dermis. This review aims to examine the recent breakthroughs in the utilization of microneedles, their applications in drug delivery comprehensively, and their future possibilities. There has been a focus on the development of new materials, advanced fabrication methods, and versatility in application areas. Consequently, contemporary research emphasizes improved drug absorption and diminished adverse effects associated with Microneedles (MNs). Their ability to produce small-molecule drugs and considerably larger biopharmaceuticals, such as vaccinations, insulin, and genetically delivered substances, renders them a versatile asset in contemporary medicine. The advancement of diverse microneedle production techniques, including bioinspired 4D microneedles, has broadened the applicability of microneedles beyond medication delivery to encompass diagnostic and cosmetic uses.

Recent Advancements in Microneedle Technology

Recent advancements have been achieved in the production of bioinspired 4D microneedles for medication delivery applications. These MNs are constructed from stimuli-responsive polymers capable of undergoing shape and functional alterations in response to physiological circumstances, hence facilitating enhanced regulated and site-specific drug delivery. This discovery has the potential for improved patient compliance and effective therapies [15]. Additionally, carbohydrate-based microneedles have been investigated for their biopolymers, which are safe for application and readily degradable, thus reducing the risk of infection or hazardous effects from residual components. The subsequent microneedles demonstrate efficacy in local drug delivery applications, particularly for vaccinations and chronic diseases[16].A notable advancement is the application of microneedles for the delivery of therapeutic cells. They facilitate the targeted delivery of therapeutic cells, which is crucial for regenerative medicine, for example. This methodology is facilitating novel developments in therapies for domains such as tissue injury healing and cancer treatment, among others [17].

Applications of Microneedle Technology: Microneedles serve multiple functions in current advanced healthcare procedures. A prevalent application is in vaccines that activate the immune system while also alleviating injection discomfort. For instance, MNs have been utilized in administering influenza and COVID-19 vaccines, demonstrating superior immune response effectiveness compared to IM injections. Moreover, microneedles (MNs) have been employed to administer insulin to diabetic patients, addressing the difficulty of daily injections. The painless and efficient recurrent application of microneedle patches represents a notable development in diabetes management, offering a convenient approach for glucose monitoring and insulin administration [18].A contrasting trend is noted in the cosmetic and dermatological sectors, particularly for anti-aging creams and acne treatments. The utilization of micro needles for skin extraction facilitates the penetration of skincare products, hence augmenting their efficacy in the overall enhancement of skin health and aesthetics[19].

Future Outlook: Microneedle technology is expected to have a promising future, with primary research focusing on the development of multifunctional microneedles that serve as both diagnostic and therapeutic instruments. Emerging specialties like pharmacogenomics may be advanced by MN technology, as they provide a body-centered medicine administration system that may be tailored to an individual patient's metabolism. Future advancements in materials and nanotechnology will undoubtedly improve the efficiency of hostel MN, particularly in the realms of enhanced medicine delivery and biosensing in the coming years. This could significantly transform therapies for chronic illnesses, vaccinations, and aesthetic interventions.

II. MICRONEEDLE TYPES AND DESIGNS

Advancement in microneedle (MN) technology has transformed transdermal medicine delivery systems, making them an effective substitute to traditional needle-based procedures. The dermal microneedles penetrate the skin's stratum corneum, allowing for medication formulation absorption with little discomfort. Various microneedle devices have been created, since distinct microneedles exhibit diverse shapes and capabilities tailored to meet unique drug delivery requirements. This includes solid, coated, dissolving, hollow, and hydrogel-forming microneedles, each offering distinct methods and advantages.

2.1. Solid Microneedles

Fabrication methods and materials used: Solid microneedles represent one of the initial iterations of microneedle technology and are generally constructed from durable materials, like silicon, stainless steel, titanium, or plastics. Fabrication methods encompass photolithography, laser cutting, and etching. These mechanisms generate arrays of solid needles that can efficiently penetrate the epidermal barrier [20].

Mechanism of action: Solid microneedles penetrate the skin to create microchannels. After penetration, the drug is either topically applied or loaded onto a patch that is placed over the treated area. This design separates the mechanical act of skin penetration from the drug delivery step, which can be adjusted depending on the drug's properties or application method [21].

2.2. Coated Microneedles

Techniques for drug coating: Coated microneedles involve applying a drug layer directly onto the microneedle surface. Common coating techniques include dip-coating, spray-coating, and inkjet printing. Each

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

technique is optimized to ensure uniform drug loading and stability on the MN surface without compromising needle integrity [22].

Advantages and challenges: The primary advantage of coated microneedles is their ability to directly deliver drugs during skin penetration. However, one major limitation is the limited drug load capacity. Only small volumes of drug can be coated onto the microneedle surface, restricting their use to potent or low-dosage medications. Moreover, ensuring even and stable coating distribution remains a challenge [23].

2.3. Dissolving Microneedles

Biodegradable materials used: Dissolving microneedles are fabricated from biodegradable materials such as polyvinyl alcohol (PVA), polylactic acid (PLA), or hyaluronic acid. These materials dissolve in the interstitial fluid after insertion into the skin, releasing the encapsulated drug over time [24].

Application for sustained and controlled drug release: Dissolving microneedles offer a significant advantage for sustained and controlled drug release. As the microneedles dissolve gradually within the skin, the drug is released in a controlled manner, enabling longer therapeutic effects from a single administration. This makes them ideal for vaccines, peptides, and other drugs requiring slow release [25].

2.4. Hollow Microneedles

Structure and functionality: Microneedles possess a conical form and are designed with a hollow lumen, allowing for the direct administration of medicines into the dermis. They function similarly to hypodermic needles, however on a somewhat smaller scale. Microneedles infiltrate the dermis at a significantly greater depth. Hollow microneedles are ideal for various applications, as they can deliver liquid compositions at precise dosages over a specified duration [26].

Use in larger molecule delivery: A significant advantage of hollow microneedles is their ability to administer relatively big molecules, including as peptides, proteins, and some vaccinations, which are typically challenging to deliver using conventional microneedle technology. Hollow MNs do not exhibit the size and stability issues inherent in traditional delivery systems, as indicated by [27].

2.4. Hydrogel-Forming Microneedles

How they swell to release drugs: The hydrogel microneedles are fabricated from a polymeric structure that penetrates the skin and expands upon absorbing interstitial fluids. This bulging creates a configuration via which the drug is eventually released in a regulated manner. These MNs do not corrode; instead, they expand, facilitating drug release without leaking residues or necessitating removal [28].

Unique benefits (extendedrelease profiles): Microneedles in hydrogel formulations offer the added benefit of controlled release qualities, making them appropriate for extended treatments. The degree of cross-linking in the hydrogel matrix enables the encapsulation and sustained release of a drug during periods that may span hours, days, or even weeks, contingent upon the specific polymer–drug mixture employed. The extended release feature is particularly advantageous when medications need to maintain a stable therapeutic concentration for the management of chronic conditions [29].



Figure 1. Overview of microneedle types and designs

III. MECHANISM OF DRUG DELIVERY VIA MICRONEEDLES

Microneedle (MN) technology is an innovative technique that may enhance conventional delivery methods. This approach enables the circumvention of the primary barrier of the skin, specifically the stratum corneum, facilitating the effective delivery of various medicinal substances. To understand the bio-safety efficacy of microneedles, it is essential to ascertain their interaction with the skin layers. This section examines skin barriers, the mechanism of microneedles on the skin, and the categories of medications administered with microneedle technology.

3.1 Skin Structure and Barriers

Role of the stratum corneum and its limitations for drug permeation: The stratum corneum, the outermost layer of the skin, serves as a primary protective barrier against pathogenic agents while also preventing excessive water loss. This layer, composed of dead keratinized cells, presents a considerable obstacle to most medications, especially hydrophilic compounds and those with a large molecular weight. The primary function of the layer is to act as a barrier; consequently, the transdermal distribution of medications is restricted, as the outer layer of the skin inhibits the penetration of most substances [30]. Although dermal patches and gels are advancing more rapidly, this layer alone allows the entry of tiny lipid-soluble compounds. Consequently, big molecules such as proteins, vaccines, and other agents cannot be delivered via passive diffusion.

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

3.2. Microneedle Interaction with Skin

How microneedles overcome the stratum corneum without significant pain: Microneedles facilitate the crossing of the stratum corneum due to their minimally invasive nature, promoting the creation of micro vessels in the skin that permit the passage of drug molecules. These channels allow drugs to reach the viable epidermis or dermis without penetrating deep enough to stimulate pain receptors, which are located in the deeper layers of the skin. This mechanism results in a painless or nearly painless administration process, improving patient compliance [31]. The microneedles typically have lengths ranging from 25 to 900 micrometers, sufficient to disrupt the stratum corneum but not deep enough to cause significant discomfort or bleeding.

Influence of needle size, design, and material on drug diffusion: The size, shape, and material of the microneedles influence both the efficiency of drug delivery and the overall patient experience. Smaller, shorter needles are less invasive and reduce discomfort, but may limit the drug load or the extent of penetration. In contrast, longer or more robust microneedles can deliver larger drug doses or access deeper skin layers, but may increase the risk of discomfort. The material used to fabricate the microneedles, such as silicon, metals, or biodegradable polymers, also affects drug diffusion rates. Biodegradable materials, for example, can facilitate controlled drug release, where the needles dissolve slowly, providing sustained release over time [32].

3.3. Types of Drugs Delivered

Small molecules, proteins, vaccines, and gene delivery: Microneedles have demonstrated remarkable versatility in delivering a wide range of drugs. This includes small molecules, which traditionally penetrate the skin poorly, as well as more complex agents such as proteins, vaccines, and even gene therapies. Small hydrophilic drugs, like insulin, have been successfully delivered using microneedles, overcoming their usual barrier posed by the stratum corneum [33]. Proteins and peptides, which are typically sensitive to enzymatic degradation in the gastrointestinal tract, benefit from transdermal delivery via microneedles by directly accessing systemic circulation without exposure to digestive enzymes [34].

Specific examples of successful drug delivery cases:

Insulin Delivery: Microneedles have been used effectively for insulin delivery in diabetic patients. Studies have shown that microneedle patches can deliver insulin in a controlled manner, maintaining blood glucose levels within a desired range for extended periods [35].

Vaccine Delivery: Microneedle technology has been successfully applied in vaccine delivery, especially in the administration of influenza vaccines. Microneedles have proven helpful in improving stability and efficacy while causing less pain than traditional intramuscular injections [36].

Gene Delivery: Recent study has indicated the utilization of hollow and dissolving microneedles in gene delivery applications. These MNs can deliver nucleic acids or viral vectors into the skin and are helpful in the genetic treatment of disorders such as melanoma [37].

IV. FABRICATION AND MATERIAL CONSIDERATIONS

Microneedle (MN) has rapidly become the chosen technique for transdermal medication delivery due to its non-invasive characteristics. The effective implementation of MN-based systems relies on the materials and fabrication processes utilized in the development of microneedles, as these factors influence the mechanical properties, biocompatibility, and drug release capabilities of the structures. This section addresses the materials utilized in microneedle fabrication, the techniques employed in their production, and the primary challenges encountered in the mass manufacturing of microneedles.

4.1. Materials Used in Microneedle Manufacturing

Polymers, metals, ceramics, and biocompatible materials: The sections have indicated that a broad array of materials has been utilized in microneedle manufacture, each possessing specific advantages reliant with practical application requirements.

Polymers: such as PLA, PVA, and PGA are easily molded and produced, and additionally, the copolymers are biodegradable. These polymers are especially favored for dissolvable microneedles that securely dissolve after drug administration [38].

Metals: Various materials, including stainless steel, titanium, and nickel, are utilized in the fabrication of microneedles due to their strength, enabling the creation of robust solid microneedles capable of penetrating the skin. These materials are non-biodegradable and are therefore utilized in solid microneedles where stiffness or mechanical strength is critical [39].

Ceramics: materials like silicon dioxide have been examined, particularly for applications requiring biocompatibility and controlled release mechanisms. However, ceramics can be quite fragile, limiting their application in some situations [40].

Biocompatible materials: like hyaluronic acid (HA) and chitosan, are increasingly utilized for soluble, biodegradable, micron-sized needles. Progress in material types encompasses natural substances such as Hyaluronic Acid (HA) and chitosan, increasingly utilized for dissolvable and biodegradable micron-sized microneedles. Consequently, they are especially attractive for scenarios requiring their immobilization within bodily tissues without provoking toxicological reactions [41].

ISSN: 2583-4053
Volume-3 Issue-5 || October 2024 || PP. 200-210
https://doi.org/10.55544/jrasb.3.5.21

4.2.Manufacturing Techniques

Table (1): Manufacturing techniques for microneedle arrays

Manufacturing Technique	Materials Used	Advantages	Disadvantages	Applications
Laser Cutting	Metal	High precision, sharp needle tips, fast production	Suitable only for small-scale production	Metal microneedles, effective skin penetration
Etching	Silicon, Ceramic	Detailed, precise arrays	Time-consuming, expensive, limited for large-scale	Silicon or ceramic microneedles
3D Printing	Biocompatible, biodegradable materials	Versatile, complex shapes, tailored to drug delivery	Still evolving, may be slower for large batches	Custom microneedles for drug delivery
Mold-based Fabrication	Polymer, Hydrogel	Scalable, consistent quality, cost-effective for large-scale	Limited to materials that can be molded	Dissolvable microneedles

4.3.Challenges in Fabrication

Scaling up production: A significant challenge of microneedles is to the reproducibility of fabrication methods while transitioning from laboratory to industrial scale. Certain techniques employed in the creation of virtual models, such as three-axis printing/etching and laser cutting/etching, may exhibit precision; nevertheless, they can be time-consuming and are not conducive to large-scale production. Utilizing mold-based procedures on a wide scale is feasible; nevertheless, it necessitates extensive fine-tuning to ensure that cell formation is uniform and devoid of flaws during mass manufacturing [46].

Cost efficiency and ensuring consistent quality: Another significant challenge is maintaining cost efficiency while ensuring consistent quality across large batches. Materials utilized for biocompatibility and biodegradability can be expensive. Moreover, the consistency and stability of the produced microneedles are crucial for their efficacy in skin penetration, necessitating rigorous quality control methods. Issues such as needle breakage or inadequate drug administration might be ascribed to inconsistencies in manufacturing processes [47]. The challenges of fulfilling quality standards and minimizing production costs through quality control measures and enhancing fabrication techniques persist in the industry.

V. APPLICATIONS OF MICRONEEDLE TECHNOLOGY

Microneedle technology (MN) is an innovative approach for transdermal medication administration that merges the effectiveness of injections with non-invasive transdermal systems. MN denotes systems composed of numerous microscopic needles that penetrate the epidermis and deliver beneficial chemicals into the body without the utilization of a conventional needle. This significant technology can be utilized in vaccines, cosmetics, chronic diseases, and diagnostics. In the subsequent sections, I will examine the primary applications of microneedle technology and their health consequences.

5.1. Vaccine Delivery

Microneedle devices represent a viable method for vaccine delivery, particularly when the ease of administration, patient compliance, and storage conditions are critical.

Examples of Vaccines Delivered via Microneedles: MN technology has been utilized in vaccines for diseases including as influenza and viral infections, including COVID-19. A particular investigation examined the utilization of microneedles (MNs) for the effective administration of the influenza vaccine, as MN patches are reported to elicit a stronger immune response compared to intramuscular (IM) injections [48]. Similarly, Minnesota has proposed a distribution system for COVID-19 vaccines to facilitate mass vaccination without the necessity of qualified healthcare personnel [49].

Benefits:

Administration Convenience: MN patches can be self-administered by patients, thereby decreasing the reliance on healthcare professionals for injections. This is particularly beneficial during large-scale vaccination initiatives.

Enhanced Patient Compliance: MNs mitigate discomfort and anxiety associated with injections, hence increasing the likelihood that patients will adhere to recommended immunization schedules.

Reduced Cold-Chain Storage: Monovalent Nucleic Vaccines (MNVs) can be stored for many weeks at ambient temperature while maintaining the efficacy of their vaccine components, so substantially reducing the necessity for cold-chain logistics, which is a significant advantage for the implementation of vaccination programs in remote and impoverished countries[50].

5.2. Transdermal Drug Delivery for Chronic Diseases

MN technology is being actively researched for its potential to deliver therapeutic drugs for chronic conditions, such as diabetes and chronic pain.

Insulin Delivery for Diabetes: Insulin Delivery for Diabetes: MN patches have been proposed as a method for administering insulin to diabetics safely. Research indicates that the MN patches may provide insulin in a precisely regulated manner, serving as a painless substitute for regular injections [51].

Transdermal Patches for Pain Relief: Microneedles are utilized to enhance the efficacy of transdermal patches for analgesic medications like lidocaine and fentanyl. Mathematically, MN patches improve medication absorption and provide a quicker onset of action compared to conventional transdermal patches [52]. It is

ISSN: 2583-4053
Volume-3 Issue-5 || October 2024 || PP. 200-210
https://doi.org/10.55544/jrasb.3.5.21

most efficacious for managing pain in people with a sustained requirement for therapeutic opioid dosages.

5.3. Cosmetic and Dermatological Applications

Microneedle technology has been used in the beauty sector as a remedy for various dermatological treatments, including anti-aging lotions and acne solutions.

Anti-aging Products: Anti-aging Products: MNs are included into cosmetic formulations to enhance collagen formation and facilitate the absorption of various anti-aging agents, including retinoids and hyaluronic acid. The subsequent treatments have shown helpful in improving skin texture, eliminating wrinkles, and promoting rejuvenation [53].

Acne Treatments and Skin Recovery: MN-based therapies are utilized for acne management and skin restoration. The minuscule perforations created by MNs initiate wound healing mechanisms, resulting in the development of new skin and subsequently enhancing skin quality concerning acne scars [54].

5.4. Diagnostics and Monitoring

It was also noted that MN technology possesses potential for diagnostic and monitoring applications, particularly in chronic conditions such as diabetes.

Glucose Monitoring: MN patches have been developed to detect glucose levels in interstitial fluid, offering a painless alternative to traditional blood glucose monitoring methods that require finger pricks. This continuous monitoring system improves diabetes management by providing real-time data on glucose levels without the discomfort of invasive techniques [55].

Other Biosensing Applications: MN arrays have been integrated with biosensors to detect biomarkers in body fluids, enabling non-invasive monitoring of various conditions. For instance, MN biosensors are being explored for detecting lactate, cholesterol, and dehydration levels in athletes and patients with metabolic disorders [56].

VI. SAFETY, EFFICACY, AND REGULATORY CONSIDERATIONS

6.1. Safety Aspects

Microneedle-based drug delivery is generally regarded as minimally invasive, but like any transdermal technology, it carries certain risks, especially with prolonged or improper use.

Skin Irritation and Infection Risks: One of the key safety concerns is skin irritation or mechanical damage from the microneedles. Although the microneedles create micro-channels, there is a risk of infection, especially if hygiene protocols are not strictly followed. Research on various MN designs indicates that these risks are typically low, but proper sterilization is required to prevent infections.

Immunogenicity: Another concern is the immunogenicity of materials used in microneedles, particularly polymeric or metallic MNs. Studies have shown that microneedle materials can provoke immune responses in some patients, although the frequency and severity of these reactions remain low [57]. MNs must be designed with biocompatible materials to reduce immunogenic responses.

6.2. Efficacy of Drug Delivery

The efficacy of MNs in drug delivery is primarily evaluated through studies on bioavailability and therapeutic outcomes.

Bioavailability Studies: MNs improve bioavailability by bypassing the stratum corneum, enabling drugs to penetrate deeper layers of the skin. Studies have consistently shown that microneedles enhance the absorption of various drugs, especially those with large molecular weights, which otherwise struggle to permeate the skin through traditional topical applications [58]. For example, a recent study demonstrated that MN patches significantly improved the bioavailability of insulin in diabetic patients, leading to better glucose control.

Therapeutic Outcomes: Clinical trials have highlighted improved **therapeutic outcomes** for patients using MN-based drug delivery systems compared to traditional methods. Drugs delivered via MNs often reach therapeutic levels faster and in a more controlled manner. For instance, vaccines administered via MNs have shown comparable or superior immunogenicity compared to traditional intramuscular injections, with added patient compliance benefits [59].

6.3. Regulatory Challenges

Regulatory oversight plays a critical role in the commercialization of MN-based products, ensuring both safety and efficacy.

FDA and EMA Requirements: The FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) require rigorous testing to demonstrate the safety and efficacy of MN-based products. These agencies demand extensive preclinical studies followed by phased clinical trials to assess both short-term and long-term safety [60]. One of the regulatory hurdles is establishing consistent manufacturing practices for MNs, especially those made from biodegradable or biocompatible materials. Regulatory bodies also scrutinize the risk of toxicity from degradation by-products of polymer-based MNs.

Pathways for Clinical Approval and Commercialization: MNs are often classified as combination products, encompassing both medical devices and drugs, which complicates their regulatory approval. Regulatory agencies require that MN products demonstrate both device safety and drug efficacy. The approval process can be expedited for certain drugs (e.g., vaccines) via fast-track pathways, especially when MNs address a significant unmet medical need [61]. Furthermore, there is growing interest in establishing harmonized international standards for MN technology to streamline regulatory approval worldwide.

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

VII. CURRENT LIMITATIONS AND CHALLENGES

7.1. Technical Barriers

Although the subsequent technical challenges are linked to MN technology.

Limited Drug Loading Capacity: However, there are certain disadvantages associated with MN technology; for instance, the MN system possesses a restricted drug loading capacity. For instance, dissolvable microneedles can only carry a limited amount of drug, which may not be sufficient for delivering the required dose for certain therapies, especially for chronic conditions requiring long-term medication [62]. This limitation is particularly significant when delivering large molecules such as proteins or nucleic acids.

Durability of Microneedles: Another challenge lies in the durability of microneedles, especially when they are designed for long-term or repeated use. Microneedles may break off or degrade prematurely, potentially leading to incomplete drug delivery or safety concerns, especially in cases where materials do not fully dissolve or bioresorb [63]. This issue complicates the use of MN for applications requiring sustained delivery over several hours or days.

7.2. Patient and Clinical Acceptance

The success of MN technology also depends on patient and clinical acceptance, and there are several factors that influence this.

Concerns Regarding Pain: Although MNs are designed to be minimally invasive, some patients still experience **pain** or discomfort, particularly when larger arrays or deeper-penetrating needles are used. While MNs are less painful than hypodermic needles, there is still a psychological barrier for many patients, especially those with needle phobia [64].

Training for Self-administration: Another concern is the **training** required for self-administration. MNs, especially patch forms, are often marketed as easy-to-use and self-applicable, but incorrect application could result in ineffective drug delivery or skin irritation [65]. Ensuring that patients, particularly those with chronic diseases, are well-trained in using MNs is crucial for improving compliance.

7.3. Cost and Scalability

Economic factors are also a significant hurdle in the widespread adoption of MN technology.

Manufacturing Challenges: The manufacturing of microneedle patches at a large scale is challenging due to the intricate design and precision required. Microneedles (MNs) must possess sufficient strength to endure insertion into the skin without fracturing, while remaining sufficiently diminutive to fit beneath the skin's surface. This necessitates precision manufacturing techniques, such as 3D microprinting or microinjection molding, which are costly and not easily scalable [66]. The elevated production and processing costs of PFI goods impede market penetration and accessibility in the targeted low-resource areas.

Market readiness: Furthermore, enhancing competitiveness is unfeasible to meet global demand. Microneedles provide the mitigation of certain benefits associated with diminished cold-chain storage and simplified distribution; nonetheless, their production process remains underdeveloped. Moreover, quality control, sterilization, and regulatory approvals are factors that will impede and complicate market readiness [67]. To utilize MN technology extensively within our healthcare system, a cost-effective and scalable production technique is essential to assure commercial viability.

VIII. FUTURE DIRECTIONS AND EMERGING TRENDS

8.1. Next-Generation Microneedles

We concentrated on the latest advancements in MN technology, particularly the smart MN capable of controlled drug delivery in response to bodily requirements. These MNs are engineered to administer medications at certain intervals or in response to particular stimuli (such as alterations in pH, glucose concentrations, or temperature). Advanced technology is facilitating more precise and effective drug delivery, enhancing therapeutic outcomes.

Nanotech Fusion: The latest advancement in MN involves broadening the application of drug delivery MN technology by its integration with nanotechnology, particularly for specific disorders that require targeted therapeutic intervention. Microneedles encapsulate nanoparticles to enhance drug stability, precision targeting, and absorption efficiency. This combination is particularly appropriate for cancer medicines that require precise targeting [68].

8.2. Microneedle Arrays for Combination Therapies

The MN arrays can facilitate multi-drug delivery, they may also be employed as combination therapy. This information is particularly valuable for therapies requiring multi-drug regimens, such as those for cancer and infectious disorders. Various drug formulations can be incorporated into a single patch utilizing microneedle arrays, facilitating either concurrent or successive drug delivery. This reduces the intricacy of treatment regimens, hence improving patient adherence and therapeutic outcomes [69].

8.3. Microneedles in Developing Regions

The use of MNs holds significant potential for improving healthcare access in developing regions. Their ease of use and minimal training requirements allow for self-administration, which is particularly beneficial in remote or resource-limited areas where healthcare professionals may not be readily available. MN technology can be deployed for vaccine delivery and chronic disease management. This method also eliminates the need for cold-chain storage, making it easier to deliver

ISSN: 2583-4053
Volume-3 Issue-5 || October 2024 || PP. 200-210
https://doi.org/10.55544/jrasb.3.5.21

temperature-sensitive medications in regions with limited infrastructure [70].

8.4. Environmental and Sustainability Considerations

In response to growing environmental concerns, researchers are currently endeavoring to produce sustainable MNs. Biodegradable microneedles, composed of polymeric materials or sugar, are engineered to dissolve within the skin post-drug administration, hence eliminating the requirement for medical waste disposal. This innovation handles the disposal of sharps and plastic trash, which health experts have managed until now with conventional syringes. Moreover, MN patches necessitate less material than conventional packaging, hence further reducing environmental effect [71].

IX. CONCLUSION

In conclusion, microneedle (MN) technology represents a significant advancement in transdermal delivery by addressing the limitations of traditional delivery technologies. Microneedles facilitate enhanced bioavailability with minimal or no discomfort to the patient by traversing the intricate skin barrier that restricts the delivery of diverse therapeutic agents, including small compounds, vaccinations, and biopharmaceuticals. Including the improvement of patient adherence, particularly in chronic illnesses, facilitating extended drug delivery, and enabling the potential for on-demand cessation of medication. Recent advancements in MN fabrication, particularly bioinspired 4D microneedles, have expanded their use from medication administration to diagnostics and cosmetic uses. Moreover, they are essential for the administration of vaccines, particularly during the COVID-19 pandemic. Despite these breakthroughs transforming the drug delivery paradigm, issues remain concerning drug loading efficiency, scalability, and patient acceptance. Ongoing research in innovative microneedles, sustainability, and combination therapies suggests that microneedle technology will continue to evolve in the market, positioning microneedles as a fundamental tool in modern medicine. Subsequently, manufacturing processes must be refined, and cost reduction objectives should be achieved to surmount clinical acceptance and regulatory obstacles for extensive future clinical adoption and commercialization.

REFERENCES

[1] Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. *Nat Rev Drug Discov*. 2004;3(2):115-24.

[2] Venkatraman S, Gale R. Skin adhesives and skin adhesion. *J Invest Dermatol*. 2013;133(4):1497-504.

[3] Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. *Pharm Sci Technol Today*. 2000;3(9):318-26.

[4] Prausnitz MR. Microneedles for transdermal drug delivery. *Adv Drug Deliv Rev*. 2004;56(5):581-7.

[5] Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. *Adv Drug Deliv Rev*. 2004;56(5):619-58.

[6] Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. *Drug Deliv*. 2006;13(3):175-87.

[7] Gupta J, Felner EI, Prausnitz MR. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. *Diabetes Technol Ther*. 2009;11(6):329-37.

[8] Langer R. Transdermal drug delivery: past progress, current status, and future prospects. *Adv Drug Deliv Rev*. 2004;56(5):557-8.

[9] Benson HA. Transdermal drug delivery: penetration enhancement techniques. *Curr Drug Deliv*. 2005;2(1):23-33.

[10] Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. *J Control Release*. 2010;141(3):277-99.

[11] Ali M, Namjoshi S, Phan K, et al. 3D Printed Microneedles for the Transdermal Delivery of NAD+ Precursor: Toward Personalization of Skin Delivery. *ACS Biomaterials*. 2024.

[12] Hu W. Fabrication of Silicon Out-of-Plane Microneedles for Potential Drug Delivery and Interstitial Fluid Extraction. *uwaterloo.ca*. 2024.

[13] Supe AR, Nemmaniwar A, Dhaneshwar G, et al. Emerging Era of Microneedle Technology for Transdermal Drug Delivery System. *iipseries.org*. 2024.

[14] Maia M, Jesus S, Borges O. Optimizing Insulin Therapy: Are Microneedles a Viable Alternative to Subcutaneous Insulin Injection? *Journal of Drug Delivery Science and Technology*. 2024.

[15] Maia M, Jesus S, Borges O. Optimizing Insulin Therapy: Are Microneedles a Viable Alternative to Subcutaneous Insulin Injection? Journal of Drug Delivery Science and Technology. 2024.

[16] Maia M, Jesus S, Borges O. Optimizing Insulin Therapy: Are Microneedles a Viable Alternative to Subcutaneous Insulin Injection? Journal of Drug Delivery Science and Technology. 2024.

[17] Maia M, Jesus S, Borges O. Optimizing Insulin Therapy: Are Microneedles a Viable Alternative to Subcutaneous Insulin Injection? Journal of Drug Delivery Science and Technology. 2024.

[18] Maia M, Jesus S, Borges O. Optimizing Insulin Therapy: Are Microneedles a Viable Alternative to Subcutaneous Insulin Injection? Journal of Drug Delivery Science and Technology. 2024.

[19] Maia M, Jesus S, Borges O. Optimizing Insulin Therapy: Are Microneedles a Viable Alternative

ISSN: 2583-4053
Volume-3 Issue-5 || October 2024 || PP. 200-210
https://doi.org/10.55544/jrasb.3.5.21

to Subcutaneous Insulin Injection? Journal of Drug Delivery Science and Technology. 2024.
[20] Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release. 2005;104(1):51-66.
[21] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268.
[22] Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007;117(2):227-237.
[23] Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater. 2008;20(5):933-938.
[24] Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-1568.
[25] Lee K, Lee CY, Jung H. Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. Biomaterials. 2011;32(11):3134-3140.
[26] McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A. 2003;100(24):13755-13760.
[27] Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release. 2012;161(2):645-655.
[28] Donnelly RF, Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv Transl Res. 2012;2(4):311-321.
[29] Donnelly RF, Moffatt K, Woolfson AD. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22(23):4879-4890.
[30] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268.
[31] Donnelly RF, Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv Transl Res. 2012;2(4):311-321.
[32] Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-1568.
[33] Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369-393.
[34] McCrudden MT, Alkilani AZ, McCrudden CM, McAlister E, McCarthy HO, Woolfson AD, et al. Design and formulation of dissolving microneedles for transdermal drug delivery of high molecular weight biopharmaceuticals. J Control Release. 2015;209:162-172.
[35] Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998;87(8):922-925.
[36] Hirobe S, Azukizawa H, Hanafusa T, Matsuo K, Quan YS, Kamiyama F, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015;57:50-58.
[37] Cormier M, Nomura T, Lee K, Tamada J, Taira M, Langer R, et al. Transdermal delivery of desmopressin using a coated microneedle array patch system. J Control Release. 2004;97(3):503-511.
[38] Donnelly RF, Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv Transl Res. 2012;2(4):311-321.
[39] McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A. 2003;100(24):13755-13760.
[40] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268.
[41] Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-1568.
[42] Wilke N, Mulcahy A, Ye SR, Morrissey A. Process optimization and characterization of silicon microneedles fabricated by wet etch technology. Microelectron J. 2005;36(7):650-656.
[43] Khanna P, Luongo K, Strom JA, Bhansali S. Microneedle-based automated therapy for diabetes mellitus. J Diabetes Sci Technol. 2011;5(5):1128-1136.
[44] Lim SH, Kathuria H, Tan JJ, Kang L. 3D printed microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2018;127:23-37.
[45] Xu J, Jin T, Zhang L. Dissolvable microneedles: fabrication, characterization, and transdermal drug delivery. J Control Release. 2018;291:187-191.
[46] Yang H, Wu X, Yin L, Zhou J, Liu Y. Electrochemical microneedles for biosensing. Biosens Bioelectron. 2020;170:112636.
[47] Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release. 2010;148(3):266-282.

ISSN: 2583-4053

Volume-3 Issue-5 || October 2024 || PP. 200-210

https://doi.org/10.55544/jrasb.3.5.21

[48] Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. *Annu Rev Chem Biomol Eng*. 2017;8:177-200.

[49] Duarah S, Sharma M, Wen J. Recent advances in microneedle-based drug delivery: Special emphasis on its use in paediatric population. *Eur J Pharm Biopharm*. 2019;136:48-69.

[50] Liu R, Li A, Lang Y, et al. Stimuli-responsive polymer microneedles: A rising transdermal drug delivery system and its applications in biomedical. *J Drug Deliv Sci Technol*. 2023;79:104036.

[51] Zhang W, Zhang W, Li C, et al. Recent advances of microneedles and their application in disease treatment. *Int J Mol Sci*. 2022;23(5):2401.

[52] Queiroz MLB, Shanmugam S, Santos LNS, et al. Microneedles as an alternative technology for transdermal drug delivery systems: A patent review. *Expert Opin Ther Pat.* 2020;30(5):319-336.

[53] Rajput A, Patil A, Kandhare P, et al. Application of microneedle arrays in cosmetics: Promises, advances, and challenges. *Med Nov Technol Dev*. 2024;12:100021.

[54] Giri Nandagopal MS, Antony R, et al. Overview of microneedle system: A third-generation transdermal drug delivery approach. *Microsyst Technol*. 2014;20(8):1527-1539.

[55] Amarnani R, Shende P. Microneedles in diagnostic, treatment and theranostics: An advancement in minimally-invasive delivery systems. *Biomed Microdevices*. 2022;24(1):1-10.

[56] Yang J, Liu X, Fu Y, et al. Recent advances of microneedles for biomedical applications: Drug delivery and beyond. *Acta Pharm Sin B*. 2019;9(3):469-483.

[57] Gunda RK, Parameshwar K. Enhancement of Skin Permeability with Microneedles Techniques: From Conceptual Framework to Commercial Products. *Nano Bio Letters* 2024.

[58] Youden B. The Development and Evaluation of Next-Generation Metallic Nanomedicines for Oncology. *University of Waterloo* 2024.

[59] Kordyl O, Styrna Z, Wojtyłko M, Michniak-Kohn B. Microneedle-based arrays: Breakthrough strategy for the treatment of bacterial and fungal skin infections. *Microbes and Infection* 2024.

[60] Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. *Annual Review of Chemical and Biomolecular Engineering* 2017.

[61] Bariya SH, Gohel MC, Mehta TA. Microneedles: An emerging transdermal drug delivery system. *Journal of Pharmacy and Pharmacology* 2012.

[62] Sartawi Z, Blackshields C, Faisal W. Dissolving microneedles: Applications and growing therapeutic potential. *Journal of Controlled Release* 2022.

[63] Larrañeta E, Lutton REM, Woolfson AD. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture, and commercial development. *Materials Science and Engineering* 2016.

[64] Nguyen HX, Nguyen CN. Microneedle-mediated transdermal delivery of biopharmaceuticals. *Pharmaceutics* 2023.

[65] Wang J, Zhang Y, Aghda NH, Pillai AR. Emerging 3D printing technologies for drug delivery devices: Current status and future perspectives. *Advanced Drug Delivery Reviews* 2021.

[66] Giri Nandagopal MS, Antony R. Overview of microneedle system: a third generation transdermal drug delivery approach. *Microsystem Technologies* 2014.

[67] Zhao J, Xu G, Yao X, Zhou H, Lyu B, Pei S. Microneedle-based insulin transdermal delivery system: current status and translation challenges. *Drug Delivery and Translational Research* 2022.

[68] Liu Y, Qu F, Geng R, Zhu J. Advanced nanocarrier-and microneedle-based transdermal drug delivery strategies for skin diseases treatment. *Theranostics* 2022.

[69] Ganeson K, Murugaiyah V, Alias AH, Amirul AAA. Microneedles for efficient and precise drug delivery in cancer therapy. *Pharmaceutics* 2023;

[70] Rajput A, Pawar A. Application of Microneedle Arrays in Cosmetics: Promises, Advances, and Challenges. *Medicine in Novel Technology* 2024.

[71] Wang J, Zhang Y, Aghda NH, Pillai AR. Emerging 3D printing technologies for drug delivery devices: Current status and future perspective. *Advanced Drug Delivery Reviews* 2021.